The DOI matches its Crossref record.
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
Open accessAbstract
BACKGROUND: The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen. METHOD: We report the outcome for a consecutive series of chemonaive patients with metastatic or locally advanced neuroendocrine tumours treated with a combination of 5-fluorouracil (500 mg m(-2)), cisplatin (70 mg m(-2)) and streptozocin (1000 mg m(-2)) (FCiSt) administered three weekly for up to six cycles. Patients were assessed for radiological response, toxicity and survival. RESULTS: In the 79 patients assessable for response, treatment with FCiSt was associated with an overall response rate of 33% (38% for pancreatic primary sites and 25% for non-pancreatic primary sites). Stable disease occurred in a further 51%, with progression in 16%. The median time to progression was 9.1 months and median overall survival was 31.5 months. The most common grade 3-4 toxicity was neutropaenia (28% patients) but grade 3-4 infection was rare (7%). The most frequent non-haematological grade 3-4 toxicity was nausea and vomiting (17%). Prognostic factors included Ki-67, mitotic index, grade and chromogranin A, whereas response to chemotherapy was predicted by mitotic index, grade and alpha-fetoprotein. CONCLUSIONS: FCiSt is an effective regimen for neuroendocrine tumours with an acceptable toxicity profile. Grade and mitotic index are the best predictors of response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Self-citationPavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R. E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv041 · Cited by 714
Self-citationÖberg, K., Knigge, U., Kwekkeboom, D., & Perren, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds295 · Cited by 524
Metadata
- Authors
- Turner, N. C., Strauss, S. J., Sarker, D., Gillmore, R., Kirkwood, A., Hackshaw, A., Papadopoulou, A., Bell, J., Kayani, I., Toumpanakis, C., Grillo, F., Mayer, A., Hochhauser, D., Begent, R. H., Caplin, M. E., & Meyer, T.
- Venue
- British Journal of Cancer
- Published
- 2010-03
- Volume
- 102
- Issue
- 7
- Pages
- 1106-1112
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2007312936
- Cited by
- 195
- References
- 0
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. https://app.cochat.ai/papers/10.1038/sj.bjc.6605618
- The paper
- Turner, N. C., Strauss, S. J., Sarker, D., Gillmore, R., Kirkwood, A., Hackshaw, A., Papadopoulou, A., Bell, J., Kayani, I., Toumpanakis, C., Grillo, F., Mayer, A., Hochhauser, D., Begent, R. H., Caplin, M. E., & Meyer, T. (2010). Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.